A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment

This trial is testing a gene therapy approach that delivers a brain-supporting protein called BDNF (Brain-Derived Neurotrophic Factor) directly into the brain of patients with early-stage Alzheimer's disease or mild cognitive impairment, using a modified harmless virus (AAV2) as a delivery vehicle. **You may be eligible if...** - You are between 50 and 80 years old with a diagnosis of mild Alzheimer's dementia (MMSE score 22–28) or mild cognitive impairment - You have no significant vascular brain disease - Your brain EEG shows no seizure activity - Your medications have been stable for at least one month - A reliable study partner (like a family member) can attend visits with you **You may NOT be eligible if...** - You have another cause of dementia (such as Lewy body, frontal dementia, or vascular dementia) - You have had a seizure, stroke, or prior brain surgery - You have serious heart, kidney, or liver disease - You have active cancer, HIV, or active hepatitis - You have a psychiatric condition (like active depression or schizophrenia) not related to Alzheimer's - You are taking blood thinners like warfarin - You are unable to have an MRI Talk to your doctor to see if this trial is right for you.